biostudies-literatureSafa OHormozgan University of Medical Sciences841https://www.ebi.ac.uk/biostudies/studies/S-EPMC7545374biostudies-literatureUnknown21(1)<h4>Objectives</h4>We investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.<h4>Trial design</h4>This is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design.<h4>Participants</h4>Inclusion criteria: 1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran 2. Age ≥18 years (weight ≥35 kg) 3. Hospitalized ≤48 hours 4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PCR)) 5. Moderate pneumonia and lung involvement in imaging 6. Signing informed consent and willingness of study participant to accept randomization to any asTrialsEffects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial.PMC7545374990089Safa OHassaniazad MHassanipour SDadvand HDavoodian PFarashahinejad MFathalipour MfalseEffects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial.<h4>Objectives</h4>We investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.<h4>Trial design</h4>This is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design.<h4>Participants</h4>Inclusion criteria: 1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran 2. Age ≥18 years (weight ≥35 kg) 3. Hospitalized ≤48 hours 4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PCR)) 5. Moderate pneumonia and lung involvement in imaging 6. Signing informed consent and willingness of study participant to accept randomization to any as2020-01-01T00:00:00Z2020 Oct2025-06-01T01:15:54.133Z2025-06-01T01:15:54.133ZS-EPMC75453743303666210.1186/s13063-020-04765-6